Startseite » COVID-19 » COVID-19 vaccine study

We are looking for participants: Vaccination study for new Corona vaccine

Impfstudie_Tropeninstitut_6
Copyright: LMU Klinikum München


Together with renowned vaccine developers, we have been researching and working on new developments and improvements of vaccines at the Tropical Institute of the LMU Hospital Munich for almost 20 years.

In our current Corona vaccine trial (start: May 2022), we are testing a novel SARS-CoV-2 vaccine (phase I).


The study in brief

Study objective
To explore the safety, tolerability and optimal dose of a novel SARS-CoV-2 vector vaccine (Phase I).

Study protocol

  • a total of 10 visits to the Tropical Institute and 4 telephone calls in 12 months
  • if you attend all appointments you will receive at least 1368 €


Requirements for participation

  • 18 - 55 years respectively 65 - 85 years old
  • in good health
  • not pregnant or breastfeeding
  • not yet vaccinated against COVID-19 or only vaccinated with BioNTech/Moderna
  • waiting period of 3 months since last COVID-19 vaccination
  • waiting period of 2 months since last COVID-19 vaccination




If interested, please feel free to contact (keyword: Corona) at:

E-mail: covid19-impfstudien@med.uni-muenchen.de

Phone: 089 4400-59850


For registration we ask for the following information:

  • Name, first name
  • Date of birth
  • Cell phone number



LMU Hospital Munich
Department of Infectious and Tropical Medicine
Leopoldstrasse 5
80802 Munich

Your information will be kept strictly confidential and will not be shared with third parties.



Are you interested in vaccination studies of the Division of infectious diseases and tropical medicine?

If you are generally interested in vaccination studies of the Tropical Institute, please contact us for a non-binding registration.
Here you will find further information.





Completed:
Clinical trial to test the CureVac SARS-CoV-2 mRNA vaccine (CVnCoV).


Please note that recruitment of subjects for the clinical trial at the Tropical Institute to test the CureVac SARS-CoV-2 mRNA vaccine (CVnCoV) has been completed (see publication in Wien Klin Wochenschr, 2021).

We thank all participants for their support!


Impfstudie_Tropeninstitut_5


Further information regarding COVID-19 vaccinations


YouTube Tutorials


Intra-muscular vaccination




Vaccine Handling